期刊文献+

一个新的靶点的反义bcl-2寡核苷酸诱导HL-60细胞凋亡的研究 被引量:6

Induction of apoptosis in HL-60 cells by a new antisense oligodeoxynucleotide targeting for the bcl-2 coding sequences
下载PDF
导出
摘要 目的 :探讨针对bcl- 2mRNA蛋白编码区的反义寡核苷酸对HL - 60细胞bcl - 2蛋白表达和凋亡的作用 方法 :应用台盼蓝拒染法和流式细胞仪检测HL - 60细胞的活性和bcl- 2蛋白表达和细胞凋亡的情况 结果 :10 μmol/L和 2 0 μmol/L的反义寡核苷酸能抑制HL - 60细胞bcl- 2蛋白表达和诱导细胞凋亡 ,并且针对bcl - 2mRNA蛋白编码区的反义寡核苷酸比针对bcl - 2mRNA翻译起始区的反义寡核苷酸作用更强 结论 :针对bcl- 2mRNA蛋白编码区的反义寡核苷酸能抑制HL - 60细胞bcl- Aim: To observe the effect of bcl-2 antisense oligodeoxynucleotide targeting the coding region of the bcl-2 mRNA on the expression of bcl-2 protein and apoptosis in HL-60 cells. Methods: Cell viability、the expression of bcl-2 protein and apototic cells were observed by propidium iodide exclusion and flow cytometric. Results: The bcl-2 antisense oligodeoxynucleotide of 10 μmol/L and 20 μmol/L can inhibit bcl-2 protein expression and promote apoptosis of HL-60 cells , and the antisense oligodeoxynucleotide targeting the coding region of the bcl-2 mRNA has stronger action than that targeting the transtration initiation. Conclusion: The bcl-2 antisense oligodeoxynucleotide targeting the coding region of the bcl-2 mRNA can inhibit bcl-2 protein expression and promote apoptosis of HL-60 cells.[
出处 《暨南大学学报(自然科学与医学版)》 CAS CSCD 2001年第1期125-128,共4页 Journal of Jinan University(Natural Science & Medicine Edition)
基金 国家自然科学基金!资助项目 (39870 36 1) 广东省重点科学基金!项目 (99M0 12 0 4G)
关键词 反义寡核苷酸 bcl-2 HL-60细胞 细胞凋亡 原癌基因 肿瘤细胞 生长抑制 antisense oligodeoxynucleotide Bcl-2 HL-60 apoptosis
  • 相关文献

参考文献1

  • 1Keith F J,Leukemia,1995年,9卷,131页

同被引文献23

  • 1范芳,葛正龙,李长福,曾小平,李海祥.c-myc ASODN对半乳糖诱导的晶状体上皮细胞中cMyc蛋白表达及细胞周期的影响[J].第四军医大学学报,2004,25(11):961-963. 被引量:2
  • 2Shivapurkar N,Reddy J,Chaudhary PM,et al.Apoptosis and lung cancer:a review.J Cell Biochem,2003,88:885-898.
  • 3Paik KH,Park YH,Ryoo BY,et al.Prognostic value of immunohistochemical staining of p53,bcl-2,and Ki-67 in small cell lung cancer.J Korean Med Sci,2006,21:35-39.
  • 4Tsujimoto Y,Gorham J,Cossman J,et al.The t (14;18)chromosome transloeations involved in B-cell neoplasms result from mistakes in VDJ joining.Science,1985,229:1390-1393.
  • 5Tamm I,Dorken B,Hartmann G.Antisense therapy in oncology:New hope for an old idea? Lancet,2001,358:489-497.
  • 6Hann CL,Daniel VC,Sugar EA,et al.Therapeutic efficacy of ABT737,a selective inhibitor of BCL-2 in small cell lung cancer.Cancer Res,2008,68:2321-2328.
  • 7Rudin CM,Otterson GA,Mauer AM,et al.A pilot trial of G3139,a bcl-2 antisense oligonucleotide,and paclitaxel in patients with chemorefractory small-cell lung cancer.Ann Oncol,2002,13:539-545.
  • 8Rudin CM,Kozloff M,Hoffman PC,et al.Phase I study of G3139,a bcl-2 antisense oligonucleotide,combined with carboplatin and etoposide in patients with small cell lung cancer.J Clin Oncol,2004,22:1110-1117.
  • 9Rudin CM,Salgia R,Wang X,et al.Randomized phase Ⅱ study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer:CALGB30103.J ClAin Oncol,2008,26:870-876.
  • 10Marcucci G,Stock W,Dai G,et al.Phase Ⅰ study of oblimersen sodium,an antisense to Bcl-2,in untreated older patients with acute myeloid leukemia:pharmacokinetics,pharmacodynemics,and clinical activity.J Clin Oncol,2005,23:3404-3411.

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部